An NCI clinical trial finds the drug selumetinib improves outcomes for children with neurofibromatosis type 1 (NF1), shrinking inoperable tumors called plexiform neurofibromas, reducing pain, and improving function and overall quality of life.
from NCI News Releases https://ift.tt/2QsCywk
from NCI News Releases https://ift.tt/2QsCywk